Cellosaurus logo
expasy logo

Cellosaurus OCI-My5 (CVCL_E332)

[Text version]
Cell line name OCI-My5
Synonyms OCI-MY5; OCI-My 5; OCIMy5; OCIMY5; MY5
Accession CVCL_E332
Resource Identification Initiative To cite this cell line use: OCI-My5 (RRID:CVCL_E332)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
From: Ontario Cancer Institute (OCI); Toronto; Canada.
Population: Caucasian.
Characteristics: Produces IgA lambda (PubMed=3137236).
Doubling time: 8 hours (PubMed=1912582).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
Sequence variations
  • Mutation; HGNC; 11998; TP53; Simple; p.Val73Trpfs*50 (c.216delC) (p.P72fs); ClinVar=VCV000428897; Zygosity=Homozygous (DepMap).
Genome ancestry Source: PubMed=30894373

Origin% genome
African3.85
Native American0
East Asian, North4.08
East Asian, South0
South Asian1.28
European, North54.74
European, South36.05
Disease Plasma cell myeloma (NCIt: C3242)
Multiple myeloma (ORDO: Orphanet_29073)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Sex unspecified
Age at sampling Age unspecified
Category Cancer cell line
Web pages https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
Publications

PubMed=3137236; DOI=10.1002/jcp.1041360225
Wandl U., Hoang T., Minden M.D., Messner H.A.
Segregation of precursors with high proliferative potential from their differentiated progeny in a myeloma cell line.
J. Cell. Physiol. 136:384-388(1988)

PubMed=1912582; DOI=10.1182/blood.V78.8.1996.1996
Hitzler J.K., Martinez-Valdez H., Bergsagel D.B., Minden M.D., Messner H.A.
Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease.
Blood 78:1996-2004(1991)

PubMed=8138440; DOI=10.1016/0360-3016(94)90107-4
Gluck S., Van Dyk J., Messner H.A.
Radiosensitivity of human clonogenic myeloma cells and normal bone marrow precursors: effect of different dose rates and fractionation.
Int. J. Radiat. Oncol. Biol. Phys. 28:877-882(1994)

PubMed=8943038; DOI=10.1073/pnas.93.24.13931
Bergsagel P.L., Chesi M., Nardini E., Brents L.A., Kirby S.L., Kuehl W.M.
Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.
Proc. Natl. Acad. Sci. U.S.A. 93:13931-13936(1996)

DOI=10.1007/0-306-46877-8_4
Jernberg-Wiklund H., Nilsson K.
Multiple myeloma cell lines.
(In) Human cell culture. Vol. 3. Cancer Cell Lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York (2000)

PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2
Drexler H.G., Matsuo Y.
Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.
Leuk. Res. 24:681-703(2000)

PubMed=11157491; DOI=10.1182/blood.V97.3.729
Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A., Kuehl W.M., Bergsagel P.L.
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
Blood 97:729-736(2001)

PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003
Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J., Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T., Zhu Y.-X., Fogle H., Price-Troska T.L., Ahmann G.J., Mancini C., Brents L.A., Kumar S.K., Greipp P., Dispenzieri A., Bryant B., Mulligan G., Bruhn L., Barrett M.T., Valdez R., Trent J.M., Stewart A.K., Carpten J.D., Bergsagel P.L.
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Cancer Cell 12:131-144(2007)

PubMed=18647998; DOI=10.1093/jncimonographs/lgn011
Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.
Characterization of MYC translocations in multiple myeloma cell lines.
J. Natl. Cancer Inst. Monogr. 39:25-31(2008)

CLPUB00604
Chow S.
Targeted capture and sequencing of immunoglobulin rearrangements in multiple myeloma to enable detection of minimal residual disease.
Thesis MSc (2017), University of Toronto, Canada

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=32123307; DOI=10.1038/s41375-020-0785-1
Sarin V., Yu K., Ferguson I.D., Gugliemini O., Nix M.A., Hann B., Sirota M., Wiita A.P.
Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis.
Leukemia 34:2754-2765(2020)

Cross-references
Cell line databases/resources cancercelllines; CVCL_E332
Cell_Model_Passport; SIDM01876
DepMap; ACH-000854
Biological sample resources BioSample; SAMN10989616
Encyclopedic resources Wikidata; Q54931788
Gene expression databases GEO; GSM1374794
Polymorphism and mutation databases Cosmic; 720791
Cosmic; 2081401
Cosmic; 2302416
Cosmic; 2367261
Entry history
Entry creation22-Oct-2012
Last entry update05-Oct-2023
Version number22